Specialties & Topics
- Arthritis/Rheumatic Disease
- Breast Cancer
- GERD/Peptic Ulcers
An ongoing dialogue on HIV/AIDS, infectious diseases,
March 30th, 2011
Journal Club: Even When You Think You Should Wait, It’s Probably Time to Start
Both apply to certain patients in whom we might consider waiting to start treatment– but both these studies suggest we do otherwise.
The first applies to the patients with slooooow CD4 decline. Perhaps so slow that both you and your patient are very comfortable watching it drift down over the years, from initially normal — let’s say 900 — to 700, then 500 over a 10-year period. After all, with such a slow decline, what could the harm be in waiting?
Certainly I’ve shared this kind of mutual denial with patients of mine, most of whom also have very low HIV RNA levels.
But according to this paper, it’s just this sort of patient who has the worst immunologic response to ART. In reviewing 2,038 patients with pre- and post-ART CD4 trajectories, the study finds that the patients with the slowest CD4 decline have the worst immunologic response to ART. In other words, slope going down predicts slope going up.
As the authors note in their discussion, it’s ironically the other group — those with fast CD4 decline — who have been targeted in HIV treatment guidelines for early ART regardless of CD4 cell counts. But perhaps these data (which are displayed in some very cool figures, by the way) tell us that if one important goal of treatment is maintaining a normal or near normal CD4, then the rate of decline is immaterial — just be sure to start ART before the CD4 count becomes abnormal.
A second paper, from Cote d’Ivoire, looks at patients who recently acquired HIV, another group we might traditionally hold off on treating. Looking at 304 patients with recent seroconversion, the investigators track the time to relevant CD4 thresholds for starting treatment. The results: more than half (57%) have a CD4 cell count < 500 at diagnosis, and 72% are at this level just two years later.
In short, the great majority of patients with recently-acquired HIV meet CD4 criteria for starting treatment sooner rather than later. So while the “time to AIDS” in untreated HIV might average 10 years, in no way should we count this as “time to starting HIV therapy”, which will come much sooner.
Comments are closed.
Paul E. Sax, MD
Learn more about HIV and ID Observations.
- Ebola Vaccine, a New Use for Listerine, USPSTF on HSV, Nether Grooming, and More: A Christmas and Hanukkah Overlap ID Link-o-Rama
- Top Stories in HIV Medicine for 2016
- Poll: Should Medicine and Family Practice Residency Programs Have a Dedicated HIV Track?
- Holiday Distractions, Dirty Pets, and Time to Vote for Your Favorite Cartoon Caption
- Two Case Reports Worth Reading, and Enlisting Pro-Vaccine Support
- ID Cartoon Caption Contest (125)
- ID Cartoon Caption Contest #2 Winner — and a New Contest for the Holidays (92)
- Mystifying Abbreviations on Daily Medical Rounds (46)
- ID Cartoon Caption Contest #1 Winner — and a New Contest for the End of Summer (46)
- Should Doctors Still Be Allowed to Wear White Coats? You Decide (43)
Subscribe to HIV and ID Observations via Email
- Bacterial DNA Level Might Predict Infection in Patients with Alcoholic Hepatitis
- Pinning Down Risk for Zika-Linked Birth Defects (FREE)
- A Blood Test for Variant Creutzfeldt-Jakob Disease?
- Antiretroviral Therapy and Life Expectancy in Rural South Africa
- Infectious Diseases Consultation Associated with Improved Cryptococcal Infection Outcome
Physician's First WatchToday's breaking medical news
- Abacavir AIDS aids clinical care antibiotics antiretroviral therapy ART atazanavir baseball CDC C diff CROI cure darunavir dolutegravir efavirenz elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID Learning Unit IDSA Infectious Diseases influenza Link-o-Rama lyme disease Massachusetts MRSA Patient Care PEP Policy PrEP prevention primary care raltegravir resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir vaccination